# First in Man Clinical Study to Investigate Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of CM3.1-AC100

> **NCT01028521** · PHASE1 · COMPLETED · sponsor: **CellMed AG, a subsidiary of BTG plc.** · enrollment: 56 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** CM3.1-AC100
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01028521
- **Lead sponsor:** CellMed AG, a subsidiary of BTG plc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2010-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01028521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01028521, "First in Man Clinical Study to Investigate Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of CM3.1-AC100". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01028521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*